Candra Novi Ricardo Sibarani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Candra Novi Ricardo Sibarani has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Siti Salima
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Padjadjaran University, Dr. Hasan Sadikin General Hospital Bandung Indonesia
6 shared publicationsDodi Suardi
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Padjadjaran University, Dr. Hasan Sadikin General Hospital Bandung Indonesia
4 shared publicationsGatot Nyarumenteng Adhipurnawan Winarno
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Padjadjaran University, Dr. Hasan Sadikin General Hospital Bandung Indonesia
4 shared publicationsGhea Mangkuliguna
School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia
4 shared publicationsNicholas Adrianto
School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta, Indonesia
4 shared publications- Nicholas Adrianto
School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
4 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Springer Nature in Discover Oncology
Extrauterine vulvar smooth muscle tumor of uncertain malignant potential in a young woman: a rare case report
Background: Smooth muscle tumors of uncertain malignant potential (STUMP) of the vulva are exceedingly rare mesenchymal neoplasms with no established management guidelines. Their morphologic overlap with rhabdomyosarcoma and leiomyosarcoma makes initial biopsy interpretation prone to error, and the adjuvant strategy after resection remains undefined. Case presentation: A 20-year-old nulligravid woman presented with a 15 × 15 × 5 cm lobulated, friable, actively bleeding vulvar–suprapubic mass and life-threatening anemia (hemoglobin 2 g/dL), following two prior excisions at outside institutions with conflicting pathology reports — embryonal (botryoid-type) rhabdomyosarcoma on first biopsy, STUMP on central review, then rhabdomyosarcoma again on a third biopsy. Immunohistochemistry at our institution (Myogenin−, MyoD1−, Desmin−, SMA+, Vimentin−, Ki-67 < 4%, with necrosis) excluded rhabdomyosarcoma and supported STUMP. After stabilisation with packed red cell transfusion, the patient underwent radical local excision with negative margins, followed by single-stage reconstruction with split-thickness skin graft (STSG). Given the shallow wound bed, STSG was preferred over flap reconstruction. Because final margins were free, no adjuvant therapy was administered, and the patient was placed on structured surveillance. Conclusion: This case illustrates three practical lessons in the management of vulvar STUMP. First, small-biopsy diagnosis of genital-tract spindle cell tumors is unreliable and should prompt centralized pathology review with a lineage-resolving immunohistochemistry panel before definitive treatment. Second, the choice between skin graft and flap reconstruction is guided primarily by wound-bed depth and vascularity rather than tumor biology. Third, in vulvar STUMP resected to negative margins, observation may be considered given the absence of evidence supporting adjuvant chemotherapy or radiotherapy; however, with only one month of follow-up, long-term oncological outcome remains unknown.
- 15 November 2026
- Published by Springer Nature in Discover Oncology
Open AccessExtrauterine vulvar smooth muscle tumor of uncertain malignant potential in a young woman: a rare case report
Background: Smooth muscle tumors of uncertain malignant potential (STUMP) of the vulva are exceedingly rare mesenchymal neoplasms with no established management guidelines. Their morphologic overlap with rhabdomyosarcoma and leiomyosarcoma makes initial biopsy interpretation prone to error, and the adjuvant strategy after resection remains undefined. Case presentation: A 20-year-old nulligravid woman presented with a 15 × 15 × 5 cm lobulated, friable, actively bleeding vulvar–suprapubic mass and life-threatening anemia (hemoglobin 2 g/dL), following two prior excisions at outside institutions with conflicting pathology reports — embryonal (botryoid-type) rhabdomyosarcoma on first biopsy, STUMP on central review, then rhabdomyosarcoma again on a third biopsy. Immunohistochemistry at our institution (Myogenin−, MyoD1−, Desmin−, SMA+, Vimentin−, Ki-67 < 4%, with necrosis) excluded rhabdomyosarcoma and supported STUMP. After stabilisation with packed red cell transfusion, the patient underwent radical local excision with negative margins, followed by single-stage reconstruction with split-thickness skin graft (STSG). Given the shallow wound bed, STSG was preferred over flap reconstruction. Because final margins were free, no adjuvant therapy was administered, and the patient was placed on structured surveillance. Conclusion: This case illustrates three practical lessons in the management of vulvar STUMP. First, small-biopsy diagnosis of genital-tract spindle cell tumors is unreliable and should prompt centralized pathology review with a lineage-resolving immunohistochemistry panel before definitive treatment. Second, the choice between skin graft and flap reconstruction is guided primarily by wound-bed depth and vascularity rather than tumor biology. Third, in vulvar STUMP resected to negative margins, observation may be considered given the absence of evidence supporting adjuvant chemotherapy or radiotherapy; however, with only one month of follow-up, long-term oncological outcome remains unknown.
- Open Access
- 26 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (7) , e72110
Risk Factors for Recurrence in Vulvar Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis
Introduction: Vulvar cancer is a rare malignancy, accounting for 5%–8% of gynecological cancers, most commonly vulvar squamous cell carcinoma (VSCC). Achieving adequate tumor‐free margins is crucial for local control. Although current guidelines recommend margins of at least 8 mm, the optimal cut‐off remains uncertain, as published evidence is inconsistent. Other clinicopathological factors may also influence recurrence, but data are limited given the rarity of VSCC. This meta‐analysis aimed to evaluate the effect of margin width and additional prognostic factors on recurrence risk. Methods: We conducted a PRISMA‐compliant systematic review and meta‐analysis, registered in PROSPERO (CRD420251135659). PubMed, Scopus, and Cochrane were searched through September 2025 for surgical VSCC studies reporting tumor‐free margin width and local recurrence. Pooled risk ratio (RR) and hazard ratio (HR) were estimated using random‐effects models, with subgroup analyses and risk of bias assessed using ROBINS‐I. Results: Twenty‐eight cohort studies were included. Margins < 8 mm were associated with increased local recurrence (LR) (RR 1.42; 24.8% vs. 15.6% for ≥ 8 mm). No significant difference was found between 3–8 mm and < 3 mm, though recurrence was higher with < 3 mm. Margin width was not associated with regional or distant metastasis. Among patients with < 8 mm margins, adjuvant treatment were radiotherapy (22.5%) and re‐excision (12.5%). Predictors of LR included tumor size (HR 1.53), lateral site (HR 1.60), depth of invasion (HR 2.51), lymph node positivity (HR 2.52), and higher FIGO stage (HR 1.77). Conclusion: Tumor‐free margins ≥ 8 mm are associated with a lower risk of local recurrence in VSCC. However, recurrence remains multifactorial, influenced by tumor size, depth of invasion, nodal involvement, and stage. Therefore, optimal management should combine adequate surgical margins with individualized adjuvant therapy tailored to the patient's risk profile. Trial Registration: PROSPERO (CRD420251135659)
- 26 July 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (7) , e72110
Open AccessRisk Factors for Recurrence in Vulvar Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis
Introduction: Vulvar cancer is a rare malignancy, accounting for 5%–8% of gynecological cancers, most commonly vulvar squamous cell carcinoma (VSCC). Achieving adequate tumor‐free margins is crucial for local control. Although current guidelines recommend margins of at least 8 mm, the optimal cut‐off remains uncertain, as published evidence is inconsistent. Other clinicopathological factors may also influence recurrence, but data are limited given the rarity of VSCC. This meta‐analysis aimed to evaluate the effect of margin width and additional prognostic factors on recurrence risk. Methods: We conducted a PRISMA‐compliant systematic review and meta‐analysis, registered in PROSPERO (CRD420251135659). PubMed, Scopus, and Cochrane were searched through September 2025 for surgical VSCC studies reporting tumor‐free margin width and local recurrence. Pooled risk ratio (RR) and hazard ratio (HR) were estimated using random‐effects models, with subgroup analyses and risk of bias assessed using ROBINS‐I. Results: Twenty‐eight cohort studies were included. Margins < 8 mm were associated with increased local recurrence (LR) (RR 1.42; 24.8% vs. 15.6% for ≥ 8 mm). No significant difference was found between 3–8 mm and < 3 mm, though recurrence was higher with < 3 mm. Margin width was not associated with regional or distant metastasis. Among patients with < 8 mm margins, adjuvant treatment were radiotherapy (22.5%) and re‐excision (12.5%). Predictors of LR included tumor size (HR 1.53), lateral site (HR 1.60), depth of invasion (HR 2.51), lymph node positivity (HR 2.52), and higher FIGO stage (HR 1.77). Conclusion: Tumor‐free margins ≥ 8 mm are associated with a lower risk of local recurrence in VSCC. However, recurrence remains multifactorial, influenced by tumor size, depth of invasion, nodal involvement, and stage. Therefore, optimal management should combine adequate surgical margins with individualized adjuvant therapy tailored to the patient's risk profile. Trial Registration: PROSPERO (CRD420251135659)
- Open Access
- 14 October 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-10
Strategies for managing EMA/CO resistant in gestational trophoblastic neoplasia a systematic review and meta analysis
Objective: This systematic review and meta-analysis evaluate the efficacy and safety of salvage regimens in managing EMA/CO-resistant GTN, providing evidence to inform optimal treatment strategies. Methods: A literature search was conducted in PubMed, ScienceDirect, Cochrane Library, Google Scholar, and Wiley Online Library until December 27, 2024. Studies on EMA/CO chemoresistance in gestational trophoblastic neoplasia (GTN) were included, and alternative regimens and surgical interventions were also considered. Exclusion applied to non-human studies and those unrelated to EMA/CO chemoresistance. Data extraction and quality assessment followed PRISMA, Cochrane ROB-2, and the Newcastle-Ottawa Scale. A meta-analysis was performed using a random-effects model, with heterogeneity (I²) and publication bias assessed. The study was registered with PROSPERO (CRD42024574582). Results: Eight studies met the inclusion criteria, encompassing patients predominantly with advanced-stage (FIGO III-IV) and high-risk GTN. EMA/EP and EP/EMA were the most frequently evaluated salvage regimens, with a pooled complete remission rate of 78.7% (95% CI: 67.4–88.1%) across 84 patients. No significant heterogeneity (I² = 27.05%) or publication bias was detected. Alternative regimens, including BEP, FAEV, and TP/TE, demonstrated favourable remission rates in small cohorts but lacked generalizability. Neutropenia (68%), thrombocytopenia (41%), and anaemia (30%) were the most commonly reported toxicities with EP/EMA. Safety data for other regimens were limited. Conclusion: EMA/EP and EP/EMA remain the most effective and well-studied salvage regimens for EMA/CO-resistant GTN, demonstrating high remission rates with manageable toxicity. While alternative regimens such as BEP, FAEV, and TP/TE show encouraging results, their limited evidence base precludes definitive comparison. Further prospective studies are needed to establish optimal salvage strategies and refine toxicity management.
- 14 October 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-10
Open AccessStrategies for managing EMA/CO resistant in gestational trophoblastic neoplasia a systematic review and meta analysis
Objective: This systematic review and meta-analysis evaluate the efficacy and safety of salvage regimens in managing EMA/CO-resistant GTN, providing evidence to inform optimal treatment strategies. Methods: A literature search was conducted in PubMed, ScienceDirect, Cochrane Library, Google Scholar, and Wiley Online Library until December 27, 2024. Studies on EMA/CO chemoresistance in gestational trophoblastic neoplasia (GTN) were included, and alternative regimens and surgical interventions were also considered. Exclusion applied to non-human studies and those unrelated to EMA/CO chemoresistance. Data extraction and quality assessment followed PRISMA, Cochrane ROB-2, and the Newcastle-Ottawa Scale. A meta-analysis was performed using a random-effects model, with heterogeneity (I²) and publication bias assessed. The study was registered with PROSPERO (CRD42024574582). Results: Eight studies met the inclusion criteria, encompassing patients predominantly with advanced-stage (FIGO III-IV) and high-risk GTN. EMA/EP and EP/EMA were the most frequently evaluated salvage regimens, with a pooled complete remission rate of 78.7% (95% CI: 67.4–88.1%) across 84 patients. No significant heterogeneity (I² = 27.05%) or publication bias was detected. Alternative regimens, including BEP, FAEV, and TP/TE, demonstrated favourable remission rates in small cohorts but lacked generalizability. Neutropenia (68%), thrombocytopenia (41%), and anaemia (30%) were the most commonly reported toxicities with EP/EMA. Safety data for other regimens were limited. Conclusion: EMA/EP and EP/EMA remain the most effective and well-studied salvage regimens for EMA/CO-resistant GTN, demonstrating high remission rates with manageable toxicity. While alternative regimens such as BEP, FAEV, and TP/TE show encouraging results, their limited evidence base precludes definitive comparison. Further prospective studies are needed to establish optimal salvage strategies and refine toxicity management.
- 18 August 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (5) , 1179-1187
Remission Outcomes Following Hysterectomy in Gestational Trophoblastic Neoplasia: A Systematic Review and Meta-Analysis
Gestational trophoblastic disease (GTD) includes premalignant and malignant entities such as choriocarcinoma and invasive mole, collectively termed gestational trophoblastic neoplasia (GTN). While chemotherapy remains the standard treatment, hysterectomy is indicated in cases of chemoresistance, significant hemorrhage, or in patients with nonmetastatic GTN who do not desire fertility preservation. This review aims to assess the effectiveness of hysterectomy in treating GTN. A systematic literature search was conducted using PubMed, EBSCOHost, ProQuest, and Google Scholar for studies published from 27 February 2000 to 27 February 2024. Exclusion criteria included single case reports, editorials, commentaries, letters, non-peer-reviewed studies, non-full-text articles, and studies without hysterectomy or relevant outcome data. Eligible studies focused on GTN and reported on remission outcomes post-hysterectomy. Three reviewers independently extracted data and analyzed it using MedCalc v19.5.1. This review is registered with PROSPERO (CRD42024556274). Seven retrospective cohort studies involving 407 patients were analyzed. The overall complete remission rate following hysterectomy was 86.6%, with higher rates in nonmetastatic cases (99.5%) and lower in metastatic cases (46.3%). Complication and mortality rates were low, with deaths occurring primarily in metastatic or high-risk patients. Hysterectomy plays a significant role in managing select GTN cases, particularly nonmetastatic or chemotherapy-resistant disease, and when fertility preservation is not desired. However, its effectiveness is limited in metastatic GTN. Postoperative monitoring of serum hCG remains crucial due to the risk of residual or metastatic disease.
- 18 August 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (5) , 1179-1187
Remission Outcomes Following Hysterectomy in Gestational Trophoblastic Neoplasia: A Systematic Review and Meta-Analysis
Gestational trophoblastic disease (GTD) includes premalignant and malignant entities such as choriocarcinoma and invasive mole, collectively termed gestational trophoblastic neoplasia (GTN). While chemotherapy remains the standard treatment, hysterectomy is indicated in cases of chemoresistance, significant hemorrhage, or in patients with nonmetastatic GTN who do not desire fertility preservation. This review aims to assess the effectiveness of hysterectomy in treating GTN. A systematic literature search was conducted using PubMed, EBSCOHost, ProQuest, and Google Scholar for studies published from 27 February 2000 to 27 February 2024. Exclusion criteria included single case reports, editorials, commentaries, letters, non-peer-reviewed studies, non-full-text articles, and studies without hysterectomy or relevant outcome data. Eligible studies focused on GTN and reported on remission outcomes post-hysterectomy. Three reviewers independently extracted data and analyzed it using MedCalc v19.5.1. This review is registered with PROSPERO (CRD42024556274). Seven retrospective cohort studies involving 407 patients were analyzed. The overall complete remission rate following hysterectomy was 86.6%, with higher rates in nonmetastatic cases (99.5%) and lower in metastatic cases (46.3%). Complication and mortality rates were low, with deaths occurring primarily in metastatic or high-risk patients. Hysterectomy plays a significant role in managing select GTN cases, particularly nonmetastatic or chemotherapy-resistant disease, and when fertility preservation is not desired. However, its effectiveness is limited in metastatic GTN. Postoperative monitoring of serum hCG remains crucial due to the risk of residual or metastatic disease.
- Open Access
- 1 August 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (8) , 2793-2802
Efficacy and Safety of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy Compared to Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
Introduction: This systematic review and meta-analysis assessed the efficacy and safety of neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy (CCRT) compared to CCRT alone in locally advanced cervical cancer (LACC). Methods: We systematically searched PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and grey literature (Google Scholar, OpenGrey, WorldCat) up to April 26, 2024 (PROSPERO: [CRD42024540599]). Seven studies were included (stages IB2–IVA, FIGO 2018), involving 446 participants. Outcomes included complete response (CR), progression-free survival (PFS), overall survival (OS), and adverse effects. Results: Seven studies were included (n = 1,638), with 825 patients receiving NACT+CCRT and 813 receiving CCRT alone. The NACT+CCRT group showed higher CR rates (77% vs. 70.9%), but the difference was not statistically significant (OR 1.23, 95% CI 0.40–3.83). No significant differences were found in PFS (HR 0.94, 95% CI 0.53–1.69) or OS (HR 1.07, 95% CI 0.56–2.03). Adverse effects, including anemia, neutropenia, thrombocytopenia, nausea, vomiting, fatigue, and creatinine elevation, showed no significant differences between the groups. Conclusion: In patients with locally advanced cervical cancer, NACT followed by CCRT is associated with comparable survival outcomes and a similar safety profile to standard CCRT, with a non-significant trend toward improved CR.
- 1 August 2025
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 26 (8) , 2793-2802
Open AccessEfficacy and Safety of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy Compared to Concurrent Chemoradiotherapy Alone in Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
Introduction: This systematic review and meta-analysis assessed the efficacy and safety of neoadjuvant chemotherapy (NACT) followed by concurrent chemoradiotherapy (CCRT) compared to CCRT alone in locally advanced cervical cancer (LACC). Methods: We systematically searched PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and grey literature (Google Scholar, OpenGrey, WorldCat) up to April 26, 2024 (PROSPERO: [CRD42024540599]). Seven studies were included (stages IB2–IVA, FIGO 2018), involving 446 participants. Outcomes included complete response (CR), progression-free survival (PFS), overall survival (OS), and adverse effects. Results: Seven studies were included (n = 1,638), with 825 patients receiving NACT+CCRT and 813 receiving CCRT alone. The NACT+CCRT group showed higher CR rates (77% vs. 70.9%), but the difference was not statistically significant (OR 1.23, 95% CI 0.40–3.83). No significant differences were found in PFS (HR 0.94, 95% CI 0.53–1.69) or OS (HR 1.07, 95% CI 0.56–2.03). Adverse effects, including anemia, neutropenia, thrombocytopenia, nausea, vomiting, fatigue, and creatinine elevation, showed no significant differences between the groups. Conclusion: In patients with locally advanced cervical cancer, NACT followed by CCRT is associated with comparable survival outcomes and a similar safety profile to standard CCRT, with a non-significant trend toward improved CR.
- 24 June 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (6) , 934-940
Prevalence of depression and anxiety in gestational trophoblastic disease: A systematic review and meta-analysis
Objective: The objective of this systematic review and meta-analysis is to determine the prevalence of anxiety and depression among individuals diagnosed with gestational trophoblastic disease (GTD), considering the significant emotional toll associated with miscarriage, surgical procedures, and prolonged β-hCG monitoring. Methods: We systematically searched for studies published up to February 2024 that reported on the prevalence of anxiety and depression in GTD. The databases included PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and Google Scholar. Data from the included studies were independently extracted by four researchers and analyzed using MedCalc v19.5.1. This study was registered with PROSPERO (registration number CRD42024525746). Results: Our analysis included seven studies involving a total of 462 participants. The findings revealed an overall prevalence of anxiety at 34.9% and depression at 22.2%, indicating a significant psychological impact on patients with GTD. Conclusion: The high prevalence of anxiety and depression underscores the necessity for physicians to provide comprehensive psychological support to patients with GTD. Educating patients about their disorder, treatment options, and potential consequences is crucial for managing the psychological aspects of GTD.
- 24 June 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (6) , 934-940
Prevalence of depression and anxiety in gestational trophoblastic disease: A systematic review and meta-analysis
Objective: The objective of this systematic review and meta-analysis is to determine the prevalence of anxiety and depression among individuals diagnosed with gestational trophoblastic disease (GTD), considering the significant emotional toll associated with miscarriage, surgical procedures, and prolonged β-hCG monitoring. Methods: We systematically searched for studies published up to February 2024 that reported on the prevalence of anxiety and depression in GTD. The databases included PubMed, ScienceDirect, Cochrane Library, EBSCOHost, ProQuest, and Google Scholar. Data from the included studies were independently extracted by four researchers and analyzed using MedCalc v19.5.1. This study was registered with PROSPERO (registration number CRD42024525746). Results: Our analysis included seven studies involving a total of 462 participants. The findings revealed an overall prevalence of anxiety at 34.9% and depression at 22.2%, indicating a significant psychological impact on patients with GTD. Conclusion: The high prevalence of anxiety and depression underscores the necessity for physicians to provide comprehensive psychological support to patients with GTD. Educating patients about their disorder, treatment options, and potential consequences is crucial for managing the psychological aspects of GTD.
- Open Access
- 3 June 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-18
Comparative efficacy and safety of vaginal brachytherapy versus combined pelvic external beam radiotherapy and vaginal brachytherapy in managing intermediate to high-risk endometrial cancer: a systematic review and meta-analysis
Purpose: This review assesses the efficacy and safety of EBRT + VBT versus VBT alone in intermediate- to high-risk endometrial cancer. Methods: A systematic review and meta-analysis were conducted using PubMed, EMBASE, ProQuest, Ovid, and Scopus (until February 18, 2025). Studies comparing EBRT + VBT to VBT alone were included. The primary outcome was pelvic recurrence rate, while secondary outcomes included distant recurrence, overall survival, and toxicity. Data extraction, risk of bias assessment (RoB-2, ROBINS-I), and meta-analysis (random-effects models in RevMan) were performed. Certainty of evidence was evaluated using GRADE. PROSPERO registration: CRD420250654411. Results: Eight studies comprising 2,672 patients met inclusion criteria (1,347 received EBRT + VBT; 1,325 had VBT alone). EBRT + VBT significantly reduced pelvic recurrence (OR 0.14, p = 0.001) but showed no difference in vaginal recurrence (OR 0.25, p = 0.14), distant metastasis (OR 0.78, p = 0.45) or overall survival (HR 0.82, p = 0.29, I2 = 72%). EBRT + VBT was associated with higher gastrointestinal, genitourinary, and hematologic toxicity. Conclusion: EBRT + VBT improves pelvic control but does not enhance survival and increases toxicity. VBT alone remains a viable option, highlighting the need for individualized treatment strategies.
- 3 June 2025
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 37 (1) , 1-18
Open AccessComparative efficacy and safety of vaginal brachytherapy versus combined pelvic external beam radiotherapy and vaginal brachytherapy in managing intermediate to high-risk endometrial cancer: a systematic review and meta-analysis
Purpose: This review assesses the efficacy and safety of EBRT + VBT versus VBT alone in intermediate- to high-risk endometrial cancer. Methods: A systematic review and meta-analysis were conducted using PubMed, EMBASE, ProQuest, Ovid, and Scopus (until February 18, 2025). Studies comparing EBRT + VBT to VBT alone were included. The primary outcome was pelvic recurrence rate, while secondary outcomes included distant recurrence, overall survival, and toxicity. Data extraction, risk of bias assessment (RoB-2, ROBINS-I), and meta-analysis (random-effects models in RevMan) were performed. Certainty of evidence was evaluated using GRADE. PROSPERO registration: CRD420250654411. Results: Eight studies comprising 2,672 patients met inclusion criteria (1,347 received EBRT + VBT; 1,325 had VBT alone). EBRT + VBT significantly reduced pelvic recurrence (OR 0.14, p = 0.001) but showed no difference in vaginal recurrence (OR 0.25, p = 0.14), distant metastasis (OR 0.78, p = 0.45) or overall survival (HR 0.82, p = 0.29, I2 = 72%). EBRT + VBT was associated with higher gastrointestinal, genitourinary, and hematologic toxicity. Conclusion: EBRT + VBT improves pelvic control but does not enhance survival and increases toxicity. VBT alone remains a viable option, highlighting the need for individualized treatment strategies.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
A rare case of squamous cell carcinoma transformation in a mature cystic teratoma of the ovary
Mature cystic teratoma of the ovary is the most common ovarian neoplasm (10%–20%). These tumors are generally benign but may undergo malignant transformation, 80% of which is squamous cell carcinoma, in postmenopausal women (1%–2%). Due to nonspecific findings, the preoperative diagnosis is challenging; most patients are detected at an advanced stage and have poor outcomes. A 40-year-old female, P2A0, complained of worsening lower abdominal pain and palpable abdominal mass. She had not been having menstrual periods for almost 4 months. For the last 3 months, she had asthenia, anorexia, and lost 10 kg. Abdominal examination was notable for an immobile, well-defined cystic mass measuring 12 × 8 × 8 cm with an irregular surface in the lower abdomen. Its overlying skin appeared reddish. A bimanual examination confirmed the adnexal origin of the cystic mass. Laboratory examination was notable for leukocytosis, thrombocytosis, increased neutrophil-to-lymphocyte ratio, and reduced absolute lymphocyte count. There was an increase in her cancer antigen 125. An abdominal ultrasonography examination showed bilateral mature cystic teratoma. A bilateral salpingo-oophorectomy was performed. A postoperative diagnosis of bilateral dermoid ovarian cysts was then established. The patient histopathology examination concluded squamous cell carcinoma (malignant transformation from benign cystic teratoma) in bilateral ovaries. The patient was referred to a gynecology oncology center for further examination and management. However, she missed the appointment for an unknown reason. The patient passed away 4 months after surgery. Clinicians should be aware of the possibility of malignant transformation of teratoma if a tumor has been present for a long time, its diameter is greater than 10 cm, there is a thickening of the cyst wall with papillary growth, there is an increase in tumor markers, and the patient is postmenopause. Malignant transformation of mature cystic teratoma remains a diagnostic and therapeutic puzzle and the prognosis is poor despite extensive initial surgery and optimal debulking.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Open AccessA rare case of squamous cell carcinoma transformation in a mature cystic teratoma of the ovary
Mature cystic teratoma of the ovary is the most common ovarian neoplasm (10%–20%). These tumors are generally benign but may undergo malignant transformation, 80% of which is squamous cell carcinoma, in postmenopausal women (1%–2%). Due to nonspecific findings, the preoperative diagnosis is challenging; most patients are detected at an advanced stage and have poor outcomes. A 40-year-old female, P2A0, complained of worsening lower abdominal pain and palpable abdominal mass. She had not been having menstrual periods for almost 4 months. For the last 3 months, she had asthenia, anorexia, and lost 10 kg. Abdominal examination was notable for an immobile, well-defined cystic mass measuring 12 × 8 × 8 cm with an irregular surface in the lower abdomen. Its overlying skin appeared reddish. A bimanual examination confirmed the adnexal origin of the cystic mass. Laboratory examination was notable for leukocytosis, thrombocytosis, increased neutrophil-to-lymphocyte ratio, and reduced absolute lymphocyte count. There was an increase in her cancer antigen 125. An abdominal ultrasonography examination showed bilateral mature cystic teratoma. A bilateral salpingo-oophorectomy was performed. A postoperative diagnosis of bilateral dermoid ovarian cysts was then established. The patient histopathology examination concluded squamous cell carcinoma (malignant transformation from benign cystic teratoma) in bilateral ovaries. The patient was referred to a gynecology oncology center for further examination and management. However, she missed the appointment for an unknown reason. The patient passed away 4 months after surgery. Clinicians should be aware of the possibility of malignant transformation of teratoma if a tumor has been present for a long time, its diameter is greater than 10 cm, there is a thickening of the cyst wall with papillary growth, there is an increase in tumor markers, and the patient is postmenopause. Malignant transformation of mature cystic teratoma remains a diagnostic and therapeutic puzzle and the prognosis is poor despite extensive initial surgery and optimal debulking.